DuPont Oral TNF Inhibitor For Arthritis, Sustiva Successor Are In Phase II
Executive Summary
DuPont Pharmaceuticals expects to file an NDA for an orally dosed TNF inhibitor in 2004, the company told analysts April 11.
You may also be interested in...
Bristol Buys DuPont: Re-Enters Imaging Agents, Adds To HIV Line
Bristol-Myers Squibb will re-enter the radiopharmaceutical business via the acquisition of DuPont Pharma.
Bristol/DuPont Is Timely Deal: Will Disrupt Difficult 2002, Add To 2003
The Bristol/DuPont deal may offer Bristol-Myers Squibb a healthy dose of distraction heading through a difficult period of patent expirations.
Bristol Buys DuPont: Re-Enters Imaging Agents, Adds To HIV Line
Bristol-Myers Squibb will re-enter the radiopharmaceutical business via the acquisition of DuPont Pharma.